Clinical data further support these findings, as GC patient samples generally exhibit downregulation of UFM1, UFBP1, and CDK5RAP3 expression, with low expression levels correlating with poorer prognosis and higher metastasis rates [20,52,58]. Here, UFM1 is linked to gastric cancer.